Sequenom needs to raise money, so it's no coincidence that Cantor upgraded Sequenom to a buy with a $16 price target. Cantor wants a piece of Sequenom's inevitable financing deal and it hopes favorable research coverage will help land the business.
(Yes, I know, there's supposed to be a very high and impenetrable Chinese Wall between sell-side research and investment banking. Has anyone seen my winged pig? I'm flying to the moon to buy some green cheese tomorrow.)
The lesson here: Don't rely too much on any single sell-side analyst! On Thursday, Cantor's Pamela Bassett lowered her Sequenom price target to $13 from $16 to reflect the impact of future stock dilution. Really? That only became obvious to Bassett after Monday's conference call? Everyone else knew that Sequenom needed to raise money soon, but apparently, Bassett didn't get the memo.
By the way, Bassett has Sequenom earning 63 cents a share on $279 million in revenue in 2011. The analyst from Stephens who covers Sequenom (with a sell rating) has the company losing $1.23 a share on total revenue of $54 million in 2011.
Thinking about Monday's FDA panel meeting for Cell Therapeutics' (CTIC) lymphoma drug pixantrone, @upstateChris on Twitter asks, "Bold enough to make a guess on the outcome?" Yes. FDA panels can be unpredictable, so I'll generously give pixantrone a 25% chance of receiving a positive vote for approval from the FDA's outside cancer experts. That means I'm 75% certain that pixantrone gets a negative vote. I covered the seven reasons for being bearishly inclined towards pixantrone going into Monday's panel meeting. A housekeeping note: The FDA panel Monday is discussing Cell Therapeutics' pixantrone during the morning session, which means a vote should come around between 11 am and noon. I expect Cell Therapeutics to be halted for trading during its session. I will be live-blogging the panel meeting, so check back for the excitement.
Steve M. writes, "I was reading one of your articles about important biotech dates and remember that there was a pay site you can subscribe to get theses dates. I failed to write down the name of the site. Would it be possible to send it to me?" I like Sagient Research and its BioMedTracker web site, which provides a comprehensive and updated database on drugs in development, including key FDA approval decision dates and clinical trial timelines. It's a great service geared more for institutional investors in terms of pricing (unfortunately), but it's still something that I think an active retail investor could find very useful.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV